Intrahepatic cholangiocarcinoma (ICC) is the second most frequent hepatic malignancy accounting for approximately 10% of primary liver cancers. Phosphatase and tension homolog (PTEN) stands out as one of the most frequently mutated genes in human malignancies. PTEN deficiency has been identified as a predictor of poor prognosis in cholangiocarcinoma.
A clinical trial was conducted to examine the therapeutic effectiveness and safety profile of bortezomib among a targeted population of PTEN-deficient intrahepatic cholangiocarcinoma (ICC) patients. #iGeneTech TargetSeq Enrichment Kit provides supports：
“We performed targeted next-generation sequencing (NGS) for the complete genomic sequence of the PTEN gene. The target size was 108 kb of captured DNA after the removal of repetitive sequences. Genomic capture from the pooled libraries was performed by a TargetSeq Enrichment Kit (iGeneTech). The libraries were sequenced on an Illumina HiSeq X Ten platform, generating 2 × 150 bp paired-end reads.”
If you are also involved in the related research, iGeneTech will support for your study. Please feel free to contact us: sales_int@igenetech.com
Learn more about iGeneTech: https://www.igenetech.com/
Read the full article: https://doi.org/10.1002/ctm2.1675
Zeng TM, Jiang TY, Yang G, et al. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial. Clin Transl Med. 2024;14(5):e1675. doi:10.1002/ctm2.1675
CN
